moneyheap
SRRK · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Scholar Rock Holding Corporation Common Stock (SRRK) stock moving?
Scholar Rock reported Q3 2026 results on Nov 10 with a $0.81 per share loss, slightly better than the $0.85 estimate, and first ISEMBYLD revenue of $0.6 million after the FDA approval on Sept 11. The company ended Q3 with $413.6 million in cash and agreed to sell its priority review voucher to BioNTech for $205 million, equal to about half its cash, with proceeds due at closing. The EMA resubmission was validated in October with a CHMP opinion expected in H1 2027, and the Japanese application was accepted under priority review. An insider bought about $12 million of shares on Oct 28. The price rose from $41.96 on Oct 22 to a $51.55 close on Nov 9 on rising volume, then closed at $48.00 on Nov 10 after an intraday high of $52.25, a 6.9% pullback on 2.06M shares. Launch revenue is still very small, and the stock has already priced in much of the voucher and results news, so the near-term picture is mixed.
News behind the analysis
- Scholar Rock Holding Q3 2026 Earnings Call TranscriptScholar Rock discussed its third-quarter 2026 results and the early U.S. launch of ISEMBYLD on the earnings call.
- Scholar Rock Reports Third Quarter 2026 Financial ResultsQ3 2026 net loss of $0.81 per share beat analyst expectations, with ISEMBYLD revenue of $0.6 million and cash of $413.6 million at Sept 30.
- BioNTech To Acquire FDA Priority Review Voucher From Scholar Rock For $205M In CashScholar Rock agreed to sell its FDA priority review voucher to BioNTech for $205 million in cash, to be received at closing.
- Scholar Rock Holding Q3 EPS $(0.81) Beats $(0.85) Estimate, Sales $600.000K Beat $22.429K EstimateScholar Rock reported Q3 EPS of $(0.81) versus a $(0.85) estimate, and sales of $600K versus an estimate of about $22K.
- Scholar Rock to Present at Upcoming Investor ConferencesManagement will participate in the UBS Global Biopharma Conference 2026.
- Scholar Rock Holding Insider Purchases $12 Million in Company SharesAn insider bought company shares worth about $11,999,922, according to a recent SEC filing.
About Scholar Rock Holding Corporation Common Stock
Scholar Rock is a Cambridge, Massachusetts biotech developing muscle-targeted therapies for rare neuromuscular diseases. Its lead drug, apitegromab, is an antibody that blocks myostatin activation (myostatin is a protein that limits muscle growth). It is aimed at spinal muscular atrophy (SMA) patients alongside existing SMN-targeted treatments, and its approval has been delayed by problems at a third-party fill-finish manufacturing plant.
How it makes money
Through 2025 the company had no product revenue and paid for operations with cash reserves (about $368 million at the end of 2025), stock sales and debt financing. It plans to earn money by selling apitegromab for SMA in the US and Europe, where launches are targeted for 2026, subject to regulatory approval. The US application was resubmitted after FDA inspection issues at the manufacturing plant. The company is also developing a subcutaneous (under-the-skin) version, a trial in FSHD (another muscular dystrophy) and a second anti-myostatin drug, SRK-439.
What usually moves SRRK
- FDA and EMA approval decisions for apitegromab
- Manufacturing and fill-finish facility issues
- Early commercial launch uptake in SMA
- Clinical trial readouts (FSHD, SRK-439, infant SMA)
- Cash runway and financing or dilution